Back to search

France· FR:61177887

BREVIBLOC 10 mg/ml, solution pour perfusion

A esmolol product containing chlorhydrate d'esmolol, registered in France by BAXTER. The same ATC class is registered in 16 of our 19 countries.

ATC C07AB09

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedBREVIBLOC 10 mg/ml, solution pour per…ATCC07AB09REGISTER NO.FR:61177887PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Esmolol is registered in 16 of 19 countries.

Countries holding a registration under ATC C07AB09 (esmolol), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose

Esmolol · ATC C07AB09

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
CHLORHYDRATE D'ESMOLOL
Manufacturer
BAXTER
Country
France (FR)
ATC code
C07AB09
ATC class
Esmolol
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400956354474
    1 poche(s) en plastique polyoléfine de 250 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

196 interactions on record for esmolol.

Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Esmolol · interactions on record

196 records

  • 11 severe
  • 139 moderate
  • 8 minor

Most severe, free to view

  • DolasetronA04AA04severe
  • TheophyllinC01EB28severe
  • CeritinibL01ED02severe
  • CeritinibL01XE28severe

38 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Esmolol in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All esmolol products

Authorised across Europe · EMA

The same active substance is authorised in 21 EEA countries. Names it is sold under:

  • Austria · Brevibloc, Esmolol Amomed
  • Belgium · Brevibloc
  • Cyprus · Brevibloc, Esmobeta
  • Czechia · Esmocard, Esmocard Lyo
  • Germany · Brevibloc, Esmocard
  • Denmark · Brevibloc
  • Spain · Brevibloc, Esmolol Aurovitas
  • Finland · Brevibloc
  • United Kingdom (Northern Ireland) · Brevibloc Premixed, Esmolol Hikma Farmacêutica (Portugal)
  • Greece · Brevibloc, Esmobeta
  • Croatia · Esmocard
  • Ireland · Brevibloc Premixed
  • Italy · Brevibloc, Esmocard
  • Luxembourg · Brevibloc
  • Malta · Brevibloc Premixed
  • Netherlands · Brevibloc, Esmolol Hcl Hikma
  • Norway · Brevibloc
  • Portugal · Brevibloc, Esmolol Eugia
  • Sweden · Brevibloc
  • Slovenia · Esmocard, Esmocard Lyo
  • Slovakia · Esmocard, Esmocard Lyo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/760ae5bd-fe1f-4f04-bf94-c964931f5cd2
GET /v1/drugs/760ae5bd-fe1f-4f04-bf94-c964931f5cd2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "61177887",
  "date_amm": "2001-09-13",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "CHLORHYDRATE D'ESMOLOL",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about esmolol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.